SCHEMBL2270670

SCHEMBL2270670

CCCCOc1cccnc1.O=C(O)[Zn]

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.67
CYP2C9 P11712 3/20 0.60
CYP2C19 P33261 3/20 0.60
LMNA P02545 2/20 0.60
CYP1A2 P05177 2/20 0.60
TSHR P16473 2/20 0.60
FAAH O00519 1/20 0.60
CYP3A4 P08684 2/20 0.57
CYP2D6 P10635 2/20 0.57
CYP19A1 P11511 1/20 0.57
NFKB1 P19838 2/20 0.56
NFKB2 Q00653 2/20 0.56
RELA Q04206 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
NPC1 O15118 1/20 0.56
POLB P06746 1/20 0.56
MAPT P10636 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.55
CHRNB2 P17787 4/20 0.54
CHRNA4 P43681 4/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2270699 0.94 LMNA (0.61) KMT2ACYP2C9CYP2C19LMNACYP1A2
SCHEMBL422229 0.89 CYP2C9 (0.70) KMT2ACYP2C9CYP2C19LMNACYP1A2
SCHEMBL20730105 0.84 CHRNB2 (0.64) KMT2ACYP2C9CYP2C19LMNACYP1A2
SCHEMBL3229561 0.82 CHRNB2 (0.62) KMT2ACYP2C9CYP2C19LMNACYP1A2
SCHEMBL19055583 0.82 CHRNB2 (0.62) KMT2ACYP2C9CYP2C19LMNACYP1A2
SCHEMBL4888697 0.82 CHRNB2 (0.62) KMT2ACYP2C9CYP2C19LMNACYP1A2
SCHEMBL9367178 0.82 CHRNB2 (0.62) KMT2ACYP2C9CYP2C19LMNACYP1A2
SCHEMBL30542607 0.82 CHRNB2 (0.62) KMT2ACYP2C9CYP2C19LMNACYP1A2
SCHEMBL2274822 0.81 CYP2D6 (0.64) CYP2C9CYP2C19LMNACYP1A2TSHR
Hydrochloric Acid SCHEMBL29969480 0.81 CHRNB2 (0.60) KMT2ACYP2C9CYP2C19LMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003688-B2 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract IMMUPHARM APS (DK) 2011-08-23 US disclosed
US-7671086-B2 Pharmaceutical compositions comprising flavonoids and menthol IMMUPHARM A/S (DK) 2010-03-02 US disclosed
US-20090227670-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL IMMUPHARM A/S (DK) 2009-09-10 US disclosed
US-7585890-B2 Pharmaceutical compositions comprising flavonoids and menthol IMMUNPHARM A/S (DK) 2009-09-08 US disclosed
EP-2089422-A1 METHODS OF SEPARATING NUCLEIC ACIDS AND PROTEIN Natimmune A/S (DK) 2009-08-19 EP disclosed
WO-2008106979-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND XYLITOL IMMUPHARM A/S (DK) 2008-09-12 WO disclosed
WO-2008064686-A1 METHODS OF SEPARATING NUCLEIC ACIDS AND PROTEIN NATIMMUNE A/S (DK) 2008-06-05 WO disclosed
EP-1556021-B1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL IMMUPHARM AS (DK) 2007-12-19 EP disclosed
US-7166640-B2 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract IMMUPHARM APS (DK) 2007-01-23 US disclosed
US-20060148726-A1 Pharmaceutical compositions comprising flavonoids and menthol IMMUPHARM A/S C/O NOVI A/S, NIELS JERNES VEJ 10 (DK) 2006-07-06 US disclosed
EP-1307189-B1 USE OF HYDROXYETHYLRUTOSIDES FOR TREATING SYMPTOMS OF COMMON COLD, ALLERGIC RHINITIS AND INFECTIONS RELATING TO THE RESPIRATORY TRACT IMMUPHARM APS (DK) 2006-05-10 EP disclosed
US-20050245467-A1 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract IMMUPHARM APS (DK) 2005-11-03 US disclosed
EP-1556021-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL Immupharm A/S (DK) 2005-07-27 EP disclosed
WO-2004037237-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL IMMUPHARM A/S (DK) 2004-05-06 WO disclosed
US-20040053858-A1 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract IMMUPHARM APS (DK) 2004-03-18 US disclosed
EP-1307189-A2 METHOD OF TREATING SYMPTOMS OF COMMON COLD, ALLERGIC RHINITIS AND INFECTIONS RELATING TO THE RESPIRATORY TRACT Immupharm APS (DK) 2003-05-07 EP disclosed
WO-2002009699-A2 METHOD OF TREATING SYMPTOMS OF COMMON COLD, ALLERGIC RHINITIS AND INFECTIONS RELATING TO THE RESPIRATORY TRACT IMMUPHARM APS (DK) 2002-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148726-A1 Pharmaceutical compositions comprising flavonoids and menthol CHIA, MAVS, C1QBP KMT2A 272/4885CYP2C9 538/4885CYP2C19 147/4885
US-20050245467-A1 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract CMA1, CHIA, C1QBP KMT2A 2593/4885CYP2C9 1079/4885CYP2C19 279/4885
US-20040053858-A1 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract CMA1, CHIA, C1QBP KMT2A 2593/4885CYP2C9 1079/4885CYP2C19 279/4885
US-20090227670-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL CHIA, MAVS, C1QBP KMT2A 272/4885CYP2C9 538/4885CYP2C19 147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.